Unaudited Interim Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2024		Sep. 30, 2023
Operating Activities
Net earnings (loss)	$ 397		$ 1,263
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities
Asset impairments	39	[1]	9
Depreciation, amortization and accretion	634		544
Pension and postretirement net periodic benefit cost	4		10
Pension and postretirement contributions	(39)		(37)
Deferred income taxes, net	12		(282)
Gain (Loss) on Disposition of Property Plant Equipment	(11)		498
Stock-based compensation	23		36
Undistributed earnings in unconsolidated affiliates	(33)		20
Other, net	13		2
Operating cash provided by (used in) discontinued operations	(6)		(5)
Changes in operating assets and liabilities
Trade receivables - third party and affiliates, net	(109)		(16)
Inventories	(177)		373
Other assets	50		219
Trade payables - third party and affiliates	(33)		(171)
Other liabilities	(314)		(398)
Net cash provided by (used in) operating activities	472		1,069
Investing Activities
Capital expenditures on property, plant and equipment	(330)		(440)
Acquisitions, net of cash acquired	0		(52)
Proceeds from sale of businesses and assets, net	0		(480)
Settlement of cross-currency swap agreement	17		0
Other, net	(29)		(58)
Net cash provided by (used in) investing activities	(342)		34
Financing Activities
Net change in short-term borrowings with maturities of 3 months or less	133		(278)
Proceeds from short-term borrowings	160		452
Repayments of short-term borrowings	(418)		(603)
Proceeds from long-term debt	299		3,001
Repayments of long-term debt	1,019		3,497
Repayments of long-term debt	(1,019)		(3,497)
Stock option exercises	1		0
Common stock dividends	(230)		(228)
Distributions/dividends to noncontrolling interests	(25)		(11)
Other, net	(25)		(52)
Net cash provided by (used in) financing activities	(1,124)		(1,216)
Exchange rate effects on cash and cash equivalents	2		(38)
Net increase (decrease) in cash and cash equivalents	(992)		(151)
Cash and cash equivalents as of beginning of period	1,805		1,508
Cash and cash equivalents as of end of period	$ 813		$ 1,357

[1] Primarily related to an impairment loss on certain trade names, primarily Zytel®, arising from the Company's annual indefinite-lived intangible assets impairment assessment (Note 5).